Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

Objective(s): To investigate the clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of adults with pulmonary arterial hypertension (PAH) within their licensed indications. Data sources: Major electronic databases (including the Cochrane L...

Full description

Bibliographic Details

Published in:	Health Technology Assessment
Main Authors:	Y-F Chen, S Jowett, P Barton, K Malottki, C Hyde, JSR Gibbs, J Pepke-Zaba, A Fry-Smith, J Roberts, D Moore
Format:	Article
Language:	English
Published:	NIHR Journals Library 2009-10-01
Subjects:	epoprostenol iloprost bosentan sitaxentan sildenafil pulmonary-arterial-hypertension
Online Access:	https://doi.org/10.3310/hta13490